These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 31980625)
1. Structure and mechanism of a Type III CRISPR defence DNA nuclease activated by cyclic oligoadenylate. McMahon SA; Zhu W; Graham S; Rambo R; White MF; Gloster TM Nat Commun; 2020 Jan; 11(1):500. PubMed ID: 31980625 [TBL] [Abstract][Full Text] [Related]
2. The CRISPR ancillary effector Can2 is a dual-specificity nuclease potentiating type III CRISPR defence. Zhu W; McQuarrie S; Grüschow S; McMahon SA; Graham S; Gloster TM; White MF Nucleic Acids Res; 2021 Mar; 49(5):2777-2789. PubMed ID: 33590098 [TBL] [Abstract][Full Text] [Related]
3. Structural basis of cyclic oligoadenylate degradation by ancillary Type III CRISPR-Cas ring nucleases. Molina R; Jensen ALG; Marchena-Hurtado J; López-Méndez B; Stella S; Montoya G Nucleic Acids Res; 2021 Dec; 49(21):12577-12590. PubMed ID: 34850143 [TBL] [Abstract][Full Text] [Related]
4. Structural basis of cyclic oligoadenylate binding to the transcription factor Csa3 outlines cross talk between type III and type I CRISPR systems. Xia P; Dutta A; Gupta K; Batish M; Parashar V J Biol Chem; 2022 Feb; 298(2):101591. PubMed ID: 35038453 [TBL] [Abstract][Full Text] [Related]
5. Fuse to defuse: a self-limiting ribonuclease-ring nuclease fusion for type III CRISPR defence. Samolygo A; Athukoralage JS; Graham S; White MF Nucleic Acids Res; 2020 Jun; 48(11):6149-6156. PubMed ID: 32347937 [TBL] [Abstract][Full Text] [Related]
6. Tetramerisation of the CRISPR ring nuclease Crn3/Csx3 facilitates cyclic oligoadenylate cleavage. Athukoralage JS; McQuarrie S; Grüschow S; Graham S; Gloster TM; White MF Elife; 2020 Jun; 9():. PubMed ID: 32597755 [TBL] [Abstract][Full Text] [Related]
7. Activation and self-inactivation mechanisms of the cyclic oligoadenylate-dependent CRISPR ribonuclease Csm6. Garcia-Doval C; Schwede F; Berk C; Rostøl JT; Niewoehner O; Tejero O; Hall J; Marraffini LA; Jinek M Nat Commun; 2020 Mar; 11(1):1596. PubMed ID: 32221291 [TBL] [Abstract][Full Text] [Related]
8. A Type III CRISPR Ancillary Ribonuclease Degrades Its Cyclic Oligoadenylate Activator. Athukoralage JS; Graham S; Grüschow S; Rouillon C; White MF J Mol Biol; 2019 Jul; 431(15):2894-2899. PubMed ID: 31071326 [TBL] [Abstract][Full Text] [Related]
10. An anti-CRISPR viral ring nuclease subverts type III CRISPR immunity. Athukoralage JS; McMahon SA; Zhang C; Grüschow S; Graham S; Krupovic M; Whitaker RJ; Gloster TM; White MF Nature; 2020 Jan; 577(7791):572-575. PubMed ID: 31942067 [TBL] [Abstract][Full Text] [Related]
11. Investigation of the cyclic oligoadenylate signaling pathway of type III CRISPR systems. Rouillon C; Athukoralage JS; Graham S; Grüschow S; White MF Methods Enzymol; 2019; 616():191-218. PubMed ID: 30691643 [TBL] [Abstract][Full Text] [Related]
12. Molecular mechanism of allosteric activation of the CRISPR ribonuclease Csm6 by cyclic tetra-adenylate. Du L; Zhu Q; Lin Z EMBO J; 2024 Jan; 43(2):304-315. PubMed ID: 38177499 [TBL] [Abstract][Full Text] [Related]
13. The Card1 nuclease provides defence during type III CRISPR immunity. Rostøl JT; Xie W; Kuryavyi V; Maguin P; Kao K; Froom R; Patel DJ; Marraffini LA Nature; 2021 Feb; 590(7847):624-629. PubMed ID: 33461211 [TBL] [Abstract][Full Text] [Related]
14. CRISPR antiphage defence mediated by the cyclic nucleotide-binding membrane protein Csx23. Grüschow S; McQuarrie S; Ackermann K; McMahon S; Bode BE; Gloster TM; White MF Nucleic Acids Res; 2024 Apr; 52(6):2761-2775. PubMed ID: 38471818 [TBL] [Abstract][Full Text] [Related]
15. Ring nucleases deactivate type III CRISPR ribonucleases by degrading cyclic oligoadenylate. Athukoralage JS; Rouillon C; Graham S; Grüschow S; White MF Nature; 2018 Oct; 562(7726):277-280. PubMed ID: 30232454 [TBL] [Abstract][Full Text] [Related]
16. Csx3 is a cyclic oligonucleotide phosphodiesterase associated with type III CRISPR-Cas that degrades the second messenger cA Brown S; Gauvin CC; Charbonneau AA; Burman N; Lawrence CM J Biol Chem; 2020 Oct; 295(44):14963-14972. PubMed ID: 32826317 [TBL] [Abstract][Full Text] [Related]
17. Molecular basis of stepwise cyclic tetra-adenylate cleavage by the type III CRISPR ring nuclease Crn1/Sso2081. Du L; Zhang D; Luo Z; Lin Z Nucleic Acids Res; 2023 Mar; 51(5):2485-2495. PubMed ID: 36807980 [TBL] [Abstract][Full Text] [Related]
18. Enzymatic properties of CARF-domain proteins in Ding J; Schuergers N; Baehre H; Wilde A Front Microbiol; 2022; 13():1046388. PubMed ID: 36419420 [TBL] [Abstract][Full Text] [Related]
19. If You'd Like to Stop a Type III CRISPR Ribonuclease, Then You Should Put a Ring (Nuclease) on It. Mo CY; Marraffini LA Mol Cell; 2018 Nov; 72(4):608-609. PubMed ID: 30444997 [TBL] [Abstract][Full Text] [Related]
20. A cyclic oligonucleotide signaling pathway in type III CRISPR-Cas systems. Kazlauskiene M; Kostiuk G; Venclovas Č; Tamulaitis G; Siksnys V Science; 2017 Aug; 357(6351):605-609. PubMed ID: 28663439 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]